SAM #ARPA-H-SOL-26-165

ARPA-H COSMOS Initiative: Organ System Modeling and Drug Screening in Microgravity

ARPA-H, a division of the National Institutes of Health under the Department of Health and Human Services, is seeking innovative research and development solutions for the Comprehensive Organ System Modeling in Outer Space (COSMOS) Initiative. - Government Buyer: - Advanced Research Projects Agency for Health (ARPA-H) - National Institutes of Health (NIH) - Department of Health and Human Services (HHS) - Opportunity Focus: - Research and development services for organ system modeling and drug screening in microgravity - Initiative aims to determine if microgravity accelerates tissue aging across organ types and age groups - Potential to establish a platform for autonomous, high-throughput drug screening in Low Earth Orbit - Awards: - Multiple Other Transaction awards anticipated - Products/Services Requested: - No specific products, part numbers, or purchase quantities listed - Proposals sought for R&D services related to organ system modeling and drug screening - OEMs and Vendors: - No OEMs or vendors named in the solicitation - Unique Requirements: - Focus on innovative approaches to modeling organ systems and drug screening in space - Emphasis on autonomous, scalable solutions for drug R&D - Opportunity for faster and more cost-effective drug development compared to Earth-based methods - Interested parties should review attached documents for further technical and submission details.

Description

The Advanced Research Projects Agency for Health (ARPA-H) Comprehensive Organ System Modeling in Outer Space (COSMOS) Initiative aims to definitively prove or disprove if exposure to microgravity in Low Earth Orbit (LEO) truly accelerates tissue aging across brain, cardiac, uterine, and kidney tissue types and across several adult age brackets. Provided Tissue Aging Rate in Space (TARIS) exceeds Tissue Aging Rate on Earth (TAROE) at a rate that exceeds the on Earth breakeven cost for new drug R&D, COSMOS will create a first-in-class platform for fully autonomous, high-throughput drug screening in LEO that would be more cost effective and faster than new drug R&D on Earth.

ARPA-H anticipates multiple Other Transaction awards resulting from this announcement.

Interested parties are invited to download and review the attached COSMOS Innovative Solutions Opening (ISO) ARPA-H-SOL-26-165

View original listing